SCHEDULE 13G/A: BML Investment Partners and Braden Michael Leonard Disclose Significant Stake in Adverum Biotechnologies

BML Investment Partners, L.P. and Leonard Braden Michael have disclosed beneficial ownership of 11.4% of Adverum Biotechnologies, Inc.'s common stock as of December 31, 2024.

Summary

• BML Investment Partners, L.P. and Leonard Braden Michael have filed an Amendment No. 4 to Schedule 13G, disclosing their beneficial ownership in Adverum Biotechnologies, Inc.
• As of December 31, 2024, the aggregate amount beneficially owned by Leonard Braden Michael is 2,373,404 shares, representing 11.4% of the class.
• Leonard Braden Michael holds sole voting and dispositive power over 104,800 shares, and shared voting and dispositive power over 2,268,604 shares.
• BML Investment Partners, L.P. beneficially owns 2,268,604 shares, representing 10.9% of the class, with shared voting and dispositive power over all these shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
• Leonard Braden Michael is the managing member of BML Capital Management, LLC, which is the sole general partner of BML Investment Partners, L.P., making him the indirect owner of shares held by BML Investment Partners, L.P.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain operational or financial performance updates that would typically influence a positive or negative sentiment score.

Positives

• The disclosure of a significant beneficial ownership stake by BML Investment Partners, L.P. and Leonard Braden Michael indicates a notable investor's confidence in Adverum Biotechnologies, Inc.
• The certification that the shares are not held for the purpose of changing or influencing control suggests stability in the company's current management and strategic direction.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Adverum Biotechnologies, Inc.'s future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of a significant ownership stake by an investment entity and an individual in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investment decision within the sector.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant ownership position, which can be of interest to existing and potential investors.

Key Dates

Keywords

Adverum Biotechnologies, Common Stock, Schedule 13G, Beneficial Ownership, BML Investment Partners, Leonard Braden Michael, Biotechnology, Investment, SEC Filing